Compare · APYX vs DXCM
APYX vs DXCM
Side-by-side comparison of Apyx Medical Corporation (APYX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APYX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 164.9x APYX ($179.4M).
- Over the past year, APYX is up 92.8% and DXCM is down 8.8% - APYX leads by 101.5 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 2 for APYX).
- DXCM has more recent analyst coverage (25 ratings vs 9 for APYX).
- Company
- Apyx Medical Corporation
- DexCom Inc.
- Price
- $4.26-2.07%
- $76.65-1.74%
- Market cap
- $179.4M
- $29.58B
- 1M return
- +1.67%
- +4.76%
- 1Y return
- +92.76%
- -8.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 2
- 4
- Recent ratings
- 9
- 25
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest APYX
- H.C. Wainwright initiated coverage on Apyx Medical with a new price target
- Director Waldman Lawrence covered exercise/tax liability with 5,024 shares and exercised 12,000 shares at a strike of $1.88 (SEC Form 4)
- SEC Form DEF 14A filed by Apyx Medical Corporation
- Chief Operating Officer Roman Shawn David exercised 15,000 shares at a strike of $3.23 and covered exercise/tax liability with 10,533 shares (SEC Form 4)
- SEC Form 8-K filed by Apyx Medical Corporation
- SEC Form 4 filed by Director Levine Wendy Lauren
- Director Vizirgianakis Stavros G. was granted 450,000 units of Restricted Stock Units, increasing direct ownership by 26% to 2,196,191 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Goodwin Charles D. Ii
- SEC Form 4 filed by Chief Financial Officer Hill Matthew C
- SEC Form 4 filed by Chief Operating Officer Roman Shawn David
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)